A Phase 1, First-in-human Study of VX-668

NCT05727800 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha-1 Antitrypsin Deficiency

Interventions

DRUG: VX-668
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated